A billion dollars for UK AI. Who ends up owning it?

It's been a big week for AI money with a British postcode. Emulate, a UK start-up founded only in August by three former Google DeepMind researchers, is reportedly close to raising up to $700m. London-based ElevenLabs is in talks to raise more than $500m. And Tandem Health, a Swedish firm whose biggest market by users is the UK, has closed a $100m round.

That's well over a billion dollars in under a fortnight, most of it still at the talks stage. The obvious question is how much of it is backed by revenue, and how much by hope.

A month-old company, a unicorn price tag

Emulate was founded by Jack Parker-Holder, Matthew McGill and Philip Ball, who worked on DeepMind's world-models team. Parker-Holder was a principal researcher on Genie 3, DeepMind's model for generating interactive 3D environments from a text prompt. The Next Web explains that world models are "AI systems that are trained to simulate and predict the way in which the physical world behaves". They're used to train robots and self-driving cars in simulated worlds.

The round is led by Index Ventures and Lightspeed Venture Partners. The Financial Times reported a $3.7 billion valuation; Bloomberg put it at $3 billion. Either way, this is a seed round, normally the first and smallest cheque a start-up raises. No product or revenue has been reported. Investors are paying for three people's CVs.

For scale: Wikipedia records that Google bought DeepMind itself in 2014 for a reported $400m to $650m. Its alumni are now raising more than that before shipping anything.

The ones with actual revenue

ElevenLabs is a different beast. The voice AI firm says it passed $500m in annual recurring revenue in the first four months of 2026. That's a company-reported run rate, not audited profit. Bloomberg reported on 17 September that the EU-backed Scaleup Europe Fund is in talks to invest in a new round of more than $500m. The Next Web adds the standard caveat that "there is no guarantee a deal will happen". We've covered ElevenLabs' IPO ambitions before, so we won't repeat that here.

Tandem Health makes an AI assistant that writes up clinical notes during consultations. It announced its $100m Series B on 14 September, led by the Scaleup Europe Fund, which EQT manages and the European Commission helped found. Tech.eu reports that the UK is Tandem's largest market by user numbers and that NHS clinicians use it. Tandem says it serves more than 10,000 care organisations across 14 European markets, though it didn't disclose revenue. It also cites research in which clinicians reported a 29% cut in time spent on admin.

Britain grows them. Who owns them?

Here's Ada's take. This week is a good advert for Britain's AI talent, and an awkward one for British capital. Look at who's writing the cheques:

• Emulate: led by Index, which Silicon UK describes as a UK firm, alongside US-based Lightspeed.
• ElevenLabs: its previous round was led by Sequoia, and the new money may come from an EU fund.
• Tandem Health: Swedish-founded and backed by European investors, even though NHS clinicians are among its biggest group of users.

That fits a longer pattern. A NatWest analysis of PitchBook data, published in June, found the average UK late-stage deal with cross-border investors was 6.3 times larger than one using only domestic money. It counted roughly 880 US unicorns against 32 in the UK. DeepMind's own story, a London lab sold to Google, is the template everyone worries about repeating. This week's Nscale listing in New York makes the same point from the other end.

For NHS trusts and UK buyers, the money matters in a practical way. A well-funded supplier is likelier to survive. But if the best British-built AI ends up owned, listed and governed elsewhere, the UK becomes a customer of its own inventions.

To be fair to the investors

Paying for talent isn't mad in AI. World models are a less crowded field than chatbots, and the people who built Genie 3 are few. ElevenLabs has grown revenue fast enough to make its valuations look less silly than many. And Tandem is doing something unglamorous and useful: cutting paperwork for overstretched clinicians. Big rounds for European companies, rather than quick sales to American giants, are arguably the fix for the problem above.

Mind the hype. A billion dollars says London can build AI. It doesn't yet say Britain gets to keep it.

Sources: The Next Web (Emulate), Silicon UK, The Next Web (ElevenLabs), Briefs, ElevenLabs, Tech.eu, Tandem Health, NatWest, Wikipedia: Google DeepMind